Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
van den Bent, Martin; Eoli, Marica; Sepulveda, Juan Manuel; Smits, Marion; Walenkamp, Annemiek; Frenel, Jean-Sebastian; Franceschi, Enrico; Clement, Paul M; Chinot, Olivier; de Vos, Filip; Whenham, Nicolas; Sanghera, Paul; Weller, Michael; Dubbink, H J; French, Pim; Looman, Jim; Dey, Jyotirmoy; Krause, Scott; Ansell, Pete; Nuyens, Sarah; Spruyt, Maarten; Brilhante, Joana; Coens, Corneel; Gorlia, Thierry; Golfinopoulos, Vassilis
(2021) Neuro-Oncology, volume 23, issue 8, pp. 1415 - 1415
(Comment)
Abstract
Corrigendum to Bent et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol (doi: 10.1093/neuonc/noz222) first published online November 20, 2019. In table 2, the rows in the hematology and investigation sections were misplaced
... read more
one line. This has been corrected.
show less
Download/Full Text
Keywords: Clinical Neurology, Oncology, Cancer Research, Journal Article
ISSN: 1522-8517
Publisher: Oxford University Press
Note: Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
(Peer reviewed)
